Eli Lilly | LLY - Cost Of Sales

Stock Price
1,022.02
Daily Change
-6.81 -0.66%
Monthly
-1.68%
Yearly
12.91%
Q1 Forecast
978.22

Eli Lilly reported $3.37B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Abbott USD 4.92B 535M Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Coherus Biosciences USD 2.65M 31.2M Mar/2025
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
J&J USD 7.97B 689M Dec/2025
Medtronic USD 3.61B 83M Dec/2025
Merck USD 3.32B 531M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Novo Nordisk DKK 15.15B 2.3B Dec/2025
Perrigo USD 747.4M 81.2M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Phibro Animal Health USD 207.39M 30.45M Dec/2024
Prestige Brands USD 131.22M 3.52M Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sanofi EUR 3.76B 344M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Zoetis USD 743M 60M Dec/2025